Consumo de recursos sanitarios y costes asociados al inicio del tratamiento con fármacos inyectables en pacientes con diabetes mellitus tipo 2

Endocrinología y Nutrición - Tập 63 - Trang 527-535 - 2016
Antoni Sicras-Mainar1, Ruth Navarro-Artieda2, Raúl Morano3, Lucía Ruíz3
1Dirección de planificación, Badalona Serveis Assistencials SA, Badalona, Barcelona, España
2Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona, España
3Departamento de Evaluación de Medicamentos, GlaxoSmithKline, Madrid, España

Tài liệu tham khảo

Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413

Soriguer, 2012, Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] Study, Diabetologia, 55, 88, 10.1007/s00125-011-2336-9

Valdés, 2007, Evolución de la prevalencia de la diabetes tipo 2 en población adulta española, Med Clin, 129, 352, 10.1157/13109554

2003, Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes, Nutr Clin Care, 6, 115

Menéndez Torre, 2011, Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes, Rev Clin Esp, 211, 147, 10.1016/j.rce.2010.11.006

Crespo, 2013, Costes directos de la diabetes mellitus y de sus complicaciones en España (Estudio SECCAID: Spain estimated cost Ciberdem-Cabimerin Diabetes), Av Diabetol, 29, 182, 10.1016/j.avdiab.2013.07.007

Lopez Bastida, 2002, [The social and economic cost of diabetes mellitus], Atencion primaria/Sociedad Española de Medicina de Familia y Comunitaria, 29, 145, 10.1016/S0212-6567(02)70526-X

Oliva, 2004, Direct health care costs of diabetic patients in Spain, Diabetes Care, 27, 2616, 10.2337/diacare.27.11.2616

Mata, 2002, [The cost of type 2 diabetes in Spain: the CODE-2 study], Gacet Sanit, 16, 511, 10.1016/S0213-9111(02)71973-0

Lopez-Bastida, 2013, Costs, outcomes and challenges for diabetes care in Spain, Global Health, 9, 17, 10.1186/1744-8603-9-17

Mata M. Coste actual de la diabetes mellitus en España: el estudio eCostes DM2. Suplemento extraordinario Diabetes Práctica. Jornadas de actualización terapéutica. Diabetes tipo 2. 2013;6.

Ballesta, 2006, Economic cost associated with type II diabetes in Spanish patients, Eur J Health Econ., 7, 270, 10.1007/s10198-006-0367-9

1993

Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8

Weiner, 1991, Development and application of a population-oriented measure of ambulatory care case-mix, Med Care, 29, 452, 10.1097/00005650-199105000-00006

Steiner, 1997, The assessment of refill compliance using pharmacy records: Methods, validity, and applications, J Clin Epidemiol, 50, 105, 10.1016/S0895-4356(96)00268-5

Thompson, 2000, How should cost data in pragmatic randomised trials be analysed?, BMJ, 320, 1197, 10.1136/bmj.320.7243.1197

Zozoya, 2015, Estudios de coste de la diabetes tipo 2: una revisión de la literatura

Costi, 2011, Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE, Endocrinol Nutr., 58, 274, 10.1016/j.endonu.2011.03.004

Thayer, 2013, The INITIATOR Study: Pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy, Adv Ther, 30, 1128, 10.1007/s12325-013-0074-8

Ortega R, Mauricio D, Detournay B, Gasalla T, Conget I. Características de los pacientes con diabetes mellitus tipo 2 en el momento de iniciar el tratamiento con agonistas de los receptores de GLP-1 en España. XXXVI congreso Nacional de la Sociedad Española de Medicina Interna (SEMI); 2015.

Barag, 2011, Insulin therapy for management of type 2 diabetes mellitus: Strategies for initiation and long-term patient adherence, J Am Osteopath Assoc, 111, S13

Nau, 2012, Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing oral and non-insulin therapies, Am J Manag Care, 18, S49

Davies, 2013, Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: A systematic review, Diabet Med, 30, 512, 10.1111/dme.12128

Balkrishnan, 2003, Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study, Clin Ther, 25, 2958, 10.1016/S0149-2918(03)80347-8

Thông tin
Thông tin xuất bản

Endocrinología y Nutrición

Tập 63

527-535

Thông tin tác giả